ProPhase Labs Misses Q3 Financial Targets, Explores Strategic Options
ProPhase Labs, Inc. (NASDAQ:PRPH) on November 19, 2025, reported third-quarter financial results that fell short of analyst expectations. The healthcare company posted an earnings per share (EPS) of -$0.16, missing the estimate of -$0.11. Revenue for the quarter was $883,000, a significant miss from the expected $5.69 million.
During its Q3 2025 earnings call, CEO Ted Karkus announced that the company is pursuing strategic initiatives and exploring mergers and acquisitions (M&A) to enhance value. The company stated it is in discussions for a specific strategic initiative and urged shareholders to vote for the current proxy to support these efforts. The company's mission and vision are central to these strategic discussions.
The company's Crown Medical division has appointed special counsel to litigate against insurance companies, with the first settlement now complete. This initiative is part of a broader strategy to achieve $50 million in net accounts receivable. For more background, see the company's history and ownership.
The earnings report underscored existing financial pressures, with a price-to-earnings (P/E) ratio of approximately -0.23 and a debt-to-equity ratio of about 1.12. A current ratio of approximately 0.14 suggests potential liquidity issues. An overview of the company's financial health and investor profile are available for further context.
ProPhase Labs, Inc. (PRPH) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.